CRSP - CRISPR Therapeutics

-

$undefined

N/A

(N/A)

CRISPR Therapeutics NASDAQ:CRSP CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Location: Baarerstrasse 14, Zug, 6300, Switzerland | Website: www.crisprtx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

1.835B

Cash

1.936B

Avg Qtr Burn

-47.2M

Short % of Float

22.76%

Insider Ownership

1.71%

Institutional Own.

84.67%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Approved

Quarterly sales

CTX110 (CD19) Details
CD19+ malignancies, B-cell malignancies, Cancer, Blood cancer

Phase 2

Data readout

Phase 1/2

Data readout

Phase 1/2

Update

Phase 1/2

Update

CTX112 Details
Systemic lupus erythematosus

Phase 1

Data readout

VCTX210 Details
Type 1 diabetes

Phase 1

Data readout

CTX130 (CD70) Details
Blood cancer, Cancer, T-cell lymphoma

Phase 1

Update

CTX131 (CD70) Details
Cancer, Solid tumor/s

Phase 1

Update

CTX112 Details
CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies

Phase 1

Update

CTX310 (ANGPTL3) Details
Atherosclerotic cardiovascular disease

Phase 1

Update

CTX320 Lp(a) Details
Atherosclerotic cardiovascular disease

Phase 1

Update

CTX120 (BCMA) Details
Multiple myeloma, Blood cancer, Cancer

Failed

Discontinued